Raymond James Financial’s Milestone Pharmaceuticals MIST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$23K Sell
26,600
-3,470
-12% -$3.85K ﹤0.01% 5359
2026
Q2
$40.3K Buy
30,070
+3,470
+13% +$5.55K ﹤0.01% 5280
2026
Q1
$31.7K Hold
26,600
– – ﹤0.01% 5167
2025
Q4
$53.7K Hold
26,600
– – ﹤0.01% 5005
2025
Q3
$53.2K Sell
26,600
-16,635
-38% -$29.3K ﹤0.01% 4816
2025
Q2
$83.9K Buy
43,235
+10,000
+30% +$13.3K ﹤0.01% 4951
2025
Q1
$26.6K Buy
+33,235
New +$66.1K ﹤0.01% 4692

Other funds holding MIST

Raymond James Financial's MIST Position: Q3 2026 in Review

Raymond James Financial reduced its Milestone Pharmaceuticals (MIST) stake by 12% in Q3 2026, selling an estimated $3.85K and leaving 26,600 shares worth $23K. The position accounts for ﹤0.01% of the portfolio, ranked #5359.

Raymond James Financial first reported a position in MIST in Q1 2025 and has held it in 7 quarters since. The position peaked at $83.9K in Q2 2025. 74 funds tracked by Wall St. Rank hold MIST as of Q3 2026.

  • Raymond James Financial held 26,600 shares of Milestone Pharmaceuticals worth $23K as of Q3 2026.
  • Raymond James Financial sold 3,470 Milestone Pharmaceuticals shares in Q3 2026, an estimated $3.85K.
  • Milestone Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #5359 holding.
  • Raymond James Financial first reported a position in Milestone Pharmaceuticals in Q1 2025 and has held it in 7 quarters since.
  • Raymond James Financial's Milestone Pharmaceuticals position peaked at $83.9K in Q2 2025.
  • 74 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.